Newsroom
  • November 29 , 2023

    FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies

    Read more
  • November 24 , 2023

    China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

    Read more
  • November 23 , 2023

    Telitacicept (brand name: 泰愛®) formally granted full approval from conditional approval by NMPA for use in combination with conventional therapy in adult patients with active and auto-antibody positive systemic lupus erythematosus

    Read more
  • November 22 , 2023

    Merck seals $610M biobucks deal to acquire preclinical neurodegenerative biotech Caraway

    Read more
  • November 21 , 2023

    Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Read more
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
If you would like to get in touch with us, please click here. Contact us